Clinical Trial

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Study acronym: RENEW 2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-08-04
Trial Details
NCT Number NCT07220759
Lead Sponsor Novo Nordisk A/S
Conditions Overweight, Obesity, Type 2 Diabetes
Enrollment 330 participants
Start Date 2025-11-05
Primary Completion 2027-05-12 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03